By Jeff Overley (July 21, 2015, 12:07 PM EDT) -- The Federal Circuit on Tuesday partly reversed Sandoz Inc.'s victory over Amgen Inc. in a major battle over requirements of the Affordable Care Act's biosimilars pathway, interpreting an advance-notice provision in a way that effectively extends exclusivity for brand-name biologics by six months.
According to the decision, biosimilar makers must wait for product approval by the U.S. Food and Drug Administration before they can supply a required 180-day advance notice of commercial marketing to a branded company. That conclusion overturned a district court decision and essentially adds 180 days of exclusivity to the 12 years that branded biologics already receive....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!